Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer

Cancer Biology and Therapy

Volumn 11, Issue 6, 2011, Pages 599-608

  Tan, Wen Lee ^a   Bhattacharya, Bhaskar ^a   Loh, Marie ^a,b   Balasubramanian, Indirikumar ^a   Akram, Mohamed ^a   Dong, Difeng ^c   Wong, Limsoon ^c   Thakkar, Bhavin ^a   Salto Tellez, Manuel ^a,c   Soo, Ross A ^c   Fichtner, Iduna ^d   Iacopetta, Barry ^b   Soong, Richie ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

5 fluorouracil; Antimetabolites; Cytidine triphosphate synthase; Drug resistance; Fluoropyrimidine; Pathway analysis; Pharmacogenomics

Indexed keywords

CYTOSINE TRIPHOSPHATE SYNTHASE 2; FLUOROURACIL; GENE PRODUCT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; URIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE S PHASE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSPORT; ENZYME SUBSTRATE; GENE FUNCTION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROBABILITY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; XENOGRAFT;

ANIMALS; APOPTOSIS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; MICE; PYROPHOSPHATASES; RNA, SMALL INTERFERING; URIDINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952763980     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.6.14670     Document Type: Article

References (32)

1. Chabner BA, Roberts TG Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5:65-72.
2. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006; 2:689-700. (Pubitemid 44764211)
3. Workman P. New cancer drugs on the horizon. Future Oncol 2005; 1:315-8.
4. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-8. (Pubitemid 37328853)
5. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55:1407-12.
6. Kanzaki A, Takebayashi Y, Bando H, Eliason JF, Watanabe Si S, Miyashita H, et al. Expression of uridine and thymidine phosphorylase genes in human breast carcinoma. Int J Cancer 2002; 97:631-5. (Pubitemid 34087802)
7. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renee N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999; 79:627-30. (Pubitemid 29046246)
8. Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 1996; 69:190-2. (Pubitemid 26233297)
9. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322-7. (Pubitemid 30226214)
10. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000; 24:236-44. (Pubitemid 30132190)
11. Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003; 63:8791-812. (Pubitemid 38064059)
12. Shimizu D, Ishikawa T, Ichikawa Y, Togo S, Hayasizaki Y, Okazaki Y, et al. Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. Int J Oncol 2005; 27:371-6.
13. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 2002; 62:518-27. (Pubitemid 34106426)
14. Soong R, Diasio RB. Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics 2005; 6:835-47. (Pubitemid 41724357)
15. Williams JC, Kizaki H, Weber G, Morris HP. Increased CTP synthetase activity in cancer cells. Nature 1978; 271:71-3. (Pubitemid 8240069)
16. Jackman AL, Calvert AH. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 1995; 6:871-81.
17. Blackledge G. New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). Br J Cancer 1998; 77:29-37.
18. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000; 18:299-313.
19. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, et al. High basal level gene expression of thymidine phosphorylase (platelet-erived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4:2371-6. (Pubitemid 28477901)
20. Wong ML, Medrano JF. Real-time PCR for mRNA quantitation. Biotechniques 2005; 39:75-85.
21. Yamauchi M, Yamauchi N, Phear G, Spurr NK, Martinsson T, Weith A, et al. Genomic organization and chromosomal localization of the human CTP synthetase gene (CTPS). Genomics 1991; 11:1088-96.
22. van Kuilenburg AB, Meinsma R, Vreken P, Waterham HR, van Gennip AH. Isoforms of human CTP synthetase. Adv Exp Med Biol 2000; 486:257-61. (Pubitemid 32179308)
23. Peters GJ, van Dijk J, Laurensse E, van Groeningen CJ, Lankelma J, Leyva A, et al. In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil. Br J Cancer 1988; 57:259-65.
24. Humeniuk R, Menon LG, Mishra PJ, Gorlick R, Sowers R, Rode W, et al. Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther 2009; 8:1037-44.
25. Whelan J, Phear G, Yamauchi M, Meuth M. Clustered base substitutions in CTP synthetase conferring drug resistance in Chinese hamster ovary cells. Nat Genet 1993; 3:317-22. (Pubitemid 23112956)
26. Kizaki H, Williams JC, Morris HP, Weber G. Increased cytidine 5'-triphosphate synthetase activity in rat and human tumors. Cancer Res 1980; 40:3921-7. (Pubitemid 10030406)
27. Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T, et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 2004; 40:298-307. (Pubitemid 38077034)
28. Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R, et al. CD133 expression predicts for nonresponse to chemotherapy in colorectal cancer. Mod Pathol 2010; 23:450-7.
29. Peters GJ, van der Wilt CL, van Triest B, Codacci- Pisanelli G, Johnston PG, van Groeningen CJ, et al. Thymidylate synthase and drug resistance. Eur J Cancer 1995; 31:1299-305.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8. (Pubitemid 34164012)
31. Lai KW, Koh KX, Loh M, Tada K, Subramaniam MM, Lim XY, et al. MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer 2010; 46:1456-63.
32. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.